This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Should Value Investors Buy Teva Pharmaceutical Industries Ltd. (TEVA) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
TEVA Gears Up to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
On TEVA's fourth-quarter conference call, investors focus is likely to be on updates on the extent to which the resurgence of COVID-19 infection rates impacted sales of its products.
Biohaven (BHVN) Initiates Pivotal Study on OCD Candidate
by Zacks Equity Research
Biohaven (BHVN) initiates enrollment in a phase III study to evaluate troriluzole as adjunctive treatment for patients with obsessive-compulsive disorder.
3 Generic Drug Stocks to Watch Amid COVID-Induced Uncertainty
by Zacks Equity Research
The impact of the coronavirus pandemic on the Zacks Medical-Generic Drugs industry is difficult to gauge. However, stable pricing and improvement in demand in some countries in 2021 may bode well for RDY, BHC and VTRS.
Is Teva Pharmaceutical (TEVA) a Good Stock to Pick Now?
by Zacks Equity Research
Is Teva Pharmaceutical (TEVA) a great pick from the value investor's perspective right now? Read on to know more.
6 Low Price-to-Book Value Stocks to Tap Market Boom
by Kinjel Shah
When it comes to valuation metrics, though P/E and P/S are the first choices, the P/B ratio is also emerging as a convenient tool to identify low-priced stocks that have high-growth prospects.
TEVA Posts In-Line Q3 Earnings, Lowers Sales View, Stock Down
by Zacks Equity Research
TEVA's earnings match estimates while sales miss the same for third-quarter 2020. It lowers its previously issued sales guidance for 2020. Stock down.
Amarin's (AMRN) Q3 Earnings Lag, Sales In Line, Stock Down
by Zacks Equity Research
Amarin's (AMRN) revenue growth in the third quarter is attributable to continued demand for its cardiovascular drug, Vascepa. Generic competition for Vascepa seems imminent.
TEVA Q3 Earnings In Line, Sales Miss, Stock Down
by Zacks Equity Research
TEVA's earnings match estimates while sales miss the same in third-quarter 2020. It maintains its previously issued guidance for 2020. Stock down.
TEVA Gears Up to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
On Teva's (TEVA) third-quarter conference call, investors will look for updates on the extent to which the coronavirus pandemic may have impacted sales of its products.
6 Low Price-to-Book Stocks That May Prove to be Solid Bets
by Kinjel Shah
When it comes to valuation metrics, though P/E and P/S are the first choices, the P/B ratio is also emerging as a convenient tool to identify low-priced stocks that have high-growth prospects.
FDA Accepts Biohaven's (BHVN) sNDA for Migraine Drug Nurtec
by Zacks Equity Research
Biohaven (BHVN) is seeking the label expansion of its migraine drug Nurtec ODT as a preventive treatment of migraine.
AbbVie Elezanumab Gets FDA's Fast Track and Orphan Drug Tags
by Zacks Equity Research
AbbVie's (ABBV) elezanumab is presently being evaluated in a phase II study for spinal cord injury.
Satsuma Plunges on Disappointing Data on Migraine Treatment
by Zacks Equity Research
Satsuma (STSA) tanks as late-stage study of STS101 (dihydroergotamine [DHE] nasal) powder as an acute treatment for migraine disappoints.
AstraZeneca's Fasenra Meets Endpoint in Rhinosinusitis Study
by Zacks Equity Research
AstraZeneca (AZN) is developing Fasenra under a clinical program as a potential treatment for chronic rhinosinusitis with nasal polyps.
Amarin Loses Patent Appeal in Vascepa Lawsuit, Stock Dips
by Zacks Equity Research
Amarin (AMRN) receives a setback as the U.S. Court of Appeals upholds a ruling by Nevada district court in favor of the generic companies related to patent litigation against Vascepa.
Teva Stock Down on Charges of Illegal Generic Price Fixing
by Zacks Equity Research
Teva (TEVA) has been indicted on charges of conspiring with other generic drugmakers to raise prices for generic drugs.
Opioid Crisis Deepens as Teva, Allergan Face Fraud Charges
by Kinjel Shah
The DFS charges claim that Teva (TEVA) and Allergan (AGN) used fraudulent marketing and promotional campaigns to promote their opioid products
FDA Nods to Emergent's (EBS) Narcan Shelf Life Extension
by Zacks Equity Research
Emergent's (EBS) Narcan nasal spray gets an FDA nod to extend its shelf life from two years to three years.
Teva (TEVA) Q2 Earnings Top, Stock Up Despite Coronavirus Woes
by Zacks Equity Research
Teva (TEVA) beats second-quarter estimates for earnings while missing the same for sales. It maintains its previously issued guidance for 2020. Stock up.
Perrigo (PRGO) Q2 Earnings Surpass Estimates, Revenues Miss
by Zacks Equity Research
Perrigo (PRGO) reports decent second-quarter 2020 results. The addition of products following Ranir acquisition boosts sales in the quarter.
Mallinckrodt's (MNK) Q2 Earnings & Sales Surpass Estimates
by Zacks Equity Research
Mallinckrodt (MNK) declines on the news of a possible bankruptcy even though sales and earnings beat expectations in the second quarter.
Teva (TEVA) Q2 Earnings Beat, Sales Miss, Keeps 2020 View
by Zacks Equity Research
Teva beats estimates for earnings while missing the same for sales in second-quarter 2020. It maintains its previously issued guidance for 2020. Stock up.
Teva (TEVA) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
On Teva's (TEVA) second-quarter conference call, investors will look for updates on the extent to which the coronavirus pandemic may have impacted sales of its products
Uncertainty Looms Large Over Generic Drug Industry Players
by Indrajit Bandyopadhyay
Stabilizing prices of generic drugs lead to recovery in the industry. New launches also provide a boost. However, coronavirus crisis creates an uncertainty for the industry.